June 24, 2015

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (cd-05)	FEXAPOTIDE TRIFLUTATE
PRONUNCIATION	fex ap' oh tide
THERAPEUTIC CLAIM	Treatment of prostate cancer; treatment of benign prostatic hyperplasia

CHEMICAL NAMES

1. L-Leucine, L-isoleucyl-L-α-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-, 2,2,2-trifluoroacetate (1:5)

2. L-isoleucyl-L-α-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-L-leucine pentakis(2,2,2-trifluoroacetate)

STRUCTURAL FORMULA



MOLECULAR FORMULA	$C_{90}H_{163}N_{27}O_{25}S$. 5 $C_2HF_3O_2$
MOLECULAR WEIGHT	2625.5
TRADEMARK	None as yet
SPONSOR	Nymox Pharmaceutical Corporation
CODE DESIGNATIONS	NX-1207
CAS REGISTRY NUMBER	1609252-56-3
UNII	98LVA678ME

gbk